Last update Jan. 15, 2026
Compatible
We do not have alternatives for FR-900506 since it is relatively safe.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
FR-900506 is Tacrolimus (oral use) in Experimental code/s.
Is written in other languages:FR-900506 belongs to these groups or families:
Main tradenames from several countries containing FR-900506 in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Immunosuppressive macrolide that inhibits calcineurin, used to prevent transplant rejection (kidney, liver, heart, etc.) and in the treatment of atopic eczema, psoriasis and other autoimmune diseases (arthritis, lupus, inflammatory bowel disease, etc.). Oral systemic and topical dermatological administration.
Its high molecular weight and high protein binding explain the clinically insignificant excretion obtained in colostrum and breast milk. (Kuczaj 2024, Akamine 2021, Hiramatsu 2018, Kociszewska 2018, Zheng 2013, Bramham 2013, Gardiner 2006, French 2003, Jain 1997)
No short- or long-term developmental or immunological problems have been observed in more than 200 infants whose mothers took it (Coscia 2025, Deans 2025, Kuczaj 2024, Mizutani 2023, Boyle 2021, Klintmalm 2020, Nure 2019, Constantinescu 2014, Izumi 2014, Thiagarajan 2013, Gouraud 2012, French 2003), except for one mild, self-resolving case of transient thrombocytosis. (Gouraud 2012)
Plasma levels in these infants were undetectable or very low. (Kuczaj 2024, Akamine 2021, Hiramatsu 2018, Izumi 2014 Bramham 2013, Gomez-Lobo 2012, Gouraud 2012)
Its low oral bioavailability, which is further reduced when taken with food (EMA 2015), especially if it is fatty, hinders its passage into the infant's plasma from the breast milk ingested.
Infants who have been exposed to calcineurin inhibitors during pregnancy may have immune deficiency in the first year of life (Grimer 2007), hence the importance of not being deprived of breastfeeding without a proven reason.
Tacrolimus may cause a slight decrease in serum prolactin levels, which has no impact on breast milk production in established breastfeeding. (Szypulska 2021)
Various medical societies and expert consensus groups consider the use of tacrolimus during breastfeeding to be safe. (Rüegg 2024, Russell 2023, Sammaritano 2020, Götestam-Skorpen 2016, Flint 2016, Durst 2015, Constantinescu 2014, Schulze 2014, Thiagarajan 2013, Armenti 2013, van der Houde 2010, Østensen 2006)
See below the information of this related product: